Quick Answer
NewAmsterdam Pharma Co N.V. reported Operating Income Loss of -$225.68 million for the year ending 2025.
- NewAmsterdam Pharma Co N.V. showed a decrease of -28.0% in Operating Income Loss from 2024 to 2025.
- This data is from NewAmsterdam Pharma Co N.V.'s annual report (Form 10-K), filed with the SEC on February 18, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 5 years of available data (2021 to 2025), NewAmsterdam Pharma Co N.V.'s Operating Income Loss has declined by 545.2%.
- Historical annual values: Fiscal year 2025: -$225.68 million | Fiscal year 2024: -$176.29 million | Fiscal year 2023: -$182.97 million | Fiscal year 2022: -$3.56 million | Fiscal year 2021: -$34.98 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: